BMC Complement Altern Med:预测缺血性卒中预后的新量表

2015-11-21 MedSci MedSci原创

背景:缺血性卒中(IS)是常见疾病,常导致死亡或残疾。先前关于卒中的预后研究主要集中在基线条件或现代昂贵的检测。然而,急性状态临床症状的改变常被忽视。这篇研究旨在形成一个新的预后量表预测IS患者90天预后。方法:在这篇回顾性的队列研究中,对4个医院的1046名(排除489名)患者进行分析。新的预后预测量表主要基于3个TCM医院患者的NIHSS分数,传统中医(TCM)症状及表征,及患者前三天的变化。

背景:缺血性卒中(IS)是常见疾病,常导致死亡或残疾。先前关于卒中的预后研究主要集中在基线条件或现代昂贵的检测。然而,急性状态临床症状的改变常被忽视。这篇研究旨在形成一个新的预后量表预测IS患者90天预后。

方法:在这篇回顾性的队列研究中,对4个医院的1046名(排除489名)患者进行分析。新的预后预测量表主要基于3个TCM医院患者的NIHSS分数,传统中医(TCM)症状及表征,及患者前三天的变化。应用ROC曲线确定预测界值点。最终,这个量表在宣武医院检测IS患者的预后。

结果:这个新的预后量表包括八个条目包括年龄(OR = 3.32;95%CI:1.72-6.42),糖尿病(DM)(OR  = 2.20;95%CI:1.19-4.08)NIHSS(OR  = 3.08;95%CI:2.16-4.40),焦虑(OR  = 3.17;95%CI:1.90-5.29),及烦躁(OR  = 4.61;95%CI:1.36-15.63),卒中开始三天,NIHSS分数改变(OR= 2.49;95%CI:1.31-4.73)及旋转(OR  = 7.80;95%CI:1.98-30.64)和耳鸣(OR  = 13.25;95%CI:1.55-113.34)。量表的总分为16.5分,界值点为9.5,如果患者分数高于9.5分,这就意味着患者在卒中90天后预后不良。新的量表在宣武医院进行效度检验,其敏感性,特异性及整体准确率分别为69.6 %, 83.3 % 及75.0 %。

结论:主要基于TCM症状,NHISS分数及前三天的改变的8条目量表能够预测IS患者预后,但是仍需要进一步的效度检验。

原文出处:

Cao KG, Fu CH, Li HQ,et al. A new prognostic scale for the early prediction of ischemic stroke recovery mainly based on traditional Chinese medicine symptoms and NIHSS score: a retrospective cohort study. BMC Complement Altern Med. 2015,Nov 16.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1974638, encodeId=595319e463898, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Nov 27 19:56:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806051, encodeId=c4f218060511e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 18 12:56:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779703, encodeId=65511e7970335, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Sat Apr 09 21:56:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861036, encodeId=52521861036b6, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 08 04:56:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773169, encodeId=ca3b1e731693b, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Jul 26 23:56:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783542, encodeId=b2621e8354297, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Oct 14 16:56:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892706, encodeId=a87a1892e067b, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 12 15:56:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606721, encodeId=c7cf1606e21ed, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 23 06:56:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1974638, encodeId=595319e463898, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Nov 27 19:56:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806051, encodeId=c4f218060511e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 18 12:56:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779703, encodeId=65511e7970335, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Sat Apr 09 21:56:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861036, encodeId=52521861036b6, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 08 04:56:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773169, encodeId=ca3b1e731693b, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Jul 26 23:56:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783542, encodeId=b2621e8354297, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Oct 14 16:56:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892706, encodeId=a87a1892e067b, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 12 15:56:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606721, encodeId=c7cf1606e21ed, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 23 06:56:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1974638, encodeId=595319e463898, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Nov 27 19:56:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806051, encodeId=c4f218060511e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 18 12:56:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779703, encodeId=65511e7970335, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Sat Apr 09 21:56:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861036, encodeId=52521861036b6, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 08 04:56:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773169, encodeId=ca3b1e731693b, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Jul 26 23:56:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783542, encodeId=b2621e8354297, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Oct 14 16:56:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892706, encodeId=a87a1892e067b, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 12 15:56:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606721, encodeId=c7cf1606e21ed, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 23 06:56:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
    2016-04-09 w363522449
  4. [GetPortalCommentsPageByObjectIdResponse(id=1974638, encodeId=595319e463898, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Nov 27 19:56:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806051, encodeId=c4f218060511e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 18 12:56:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779703, encodeId=65511e7970335, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Sat Apr 09 21:56:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861036, encodeId=52521861036b6, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 08 04:56:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773169, encodeId=ca3b1e731693b, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Jul 26 23:56:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783542, encodeId=b2621e8354297, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Oct 14 16:56:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892706, encodeId=a87a1892e067b, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 12 15:56:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606721, encodeId=c7cf1606e21ed, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 23 06:56:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
    2016-02-08 shizhenshan
  5. [GetPortalCommentsPageByObjectIdResponse(id=1974638, encodeId=595319e463898, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Nov 27 19:56:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806051, encodeId=c4f218060511e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 18 12:56:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779703, encodeId=65511e7970335, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Sat Apr 09 21:56:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861036, encodeId=52521861036b6, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 08 04:56:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773169, encodeId=ca3b1e731693b, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Jul 26 23:56:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783542, encodeId=b2621e8354297, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Oct 14 16:56:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892706, encodeId=a87a1892e067b, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 12 15:56:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606721, encodeId=c7cf1606e21ed, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 23 06:56:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
    2016-07-26 xuyong536
  6. [GetPortalCommentsPageByObjectIdResponse(id=1974638, encodeId=595319e463898, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Nov 27 19:56:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806051, encodeId=c4f218060511e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 18 12:56:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779703, encodeId=65511e7970335, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Sat Apr 09 21:56:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861036, encodeId=52521861036b6, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 08 04:56:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773169, encodeId=ca3b1e731693b, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Jul 26 23:56:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783542, encodeId=b2621e8354297, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Oct 14 16:56:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892706, encodeId=a87a1892e067b, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 12 15:56:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606721, encodeId=c7cf1606e21ed, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 23 06:56:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
    2016-10-14 zsyan
  7. [GetPortalCommentsPageByObjectIdResponse(id=1974638, encodeId=595319e463898, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Nov 27 19:56:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806051, encodeId=c4f218060511e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 18 12:56:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779703, encodeId=65511e7970335, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Sat Apr 09 21:56:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861036, encodeId=52521861036b6, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 08 04:56:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773169, encodeId=ca3b1e731693b, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Jul 26 23:56:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783542, encodeId=b2621e8354297, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Oct 14 16:56:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892706, encodeId=a87a1892e067b, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 12 15:56:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606721, encodeId=c7cf1606e21ed, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 23 06:56:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1974638, encodeId=595319e463898, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Nov 27 19:56:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806051, encodeId=c4f218060511e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 18 12:56:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779703, encodeId=65511e7970335, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Sat Apr 09 21:56:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861036, encodeId=52521861036b6, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 08 04:56:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773169, encodeId=ca3b1e731693b, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Jul 26 23:56:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783542, encodeId=b2621e8354297, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Oct 14 16:56:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892706, encodeId=a87a1892e067b, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 12 15:56:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606721, encodeId=c7cf1606e21ed, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 23 06:56:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]

相关资讯

Neurology:韩国轻中度饮酒可降低缺血性卒中的发生

目的:研究者进行了一项基于人群的病例对照研究,研究与西方酒精饮料偏好不同的韩国人在酒精摄入和缺血性卒中风险之间剂量反应关系,并且检测性别和缺血性卒中类型的影响。 方法:招募了年龄20岁以上首发卒中的患者1848名作为病例组。按照年龄(±3岁),性别及教育程度从第四和第五次韩国国家和营养调查中选取3589名无卒中的对照者与对照组进行配对。所有的受试者完成一项关于酒精摄入的结构性问卷调查的面谈。结果:

J Neurochem:区分缺血性卒中和出血性卒中的生物标记物:RBP4 和GFAP

快速区分急性缺血性脑卒中和出血性脑卒中是非常必要的,能够促进改善预后。研究者旨在识别新型的生物标记物区分卒中亚型,并比较其他已经描述过的生物标记物的诊断能力。应用177抗体库筛选缺血性脑卒中(36)和出血性卒中(10)患者的血浆样本,其中有11种在不同脑卒中亚型中,浓度不同,主要是趋化因子、生长因子和血管生成因子。从16名缺血性卒中和16出血性卒中患者中选出五种蛋白,及视黄醇结合蛋白4(RPB4)

Stroke:血浆D-二聚体浓度高,小心缺血性卒中!

流行病学研究已经证实,D-二聚体,纤维蛋白降解产物,是冠心病的危险标志物,但是对于中风的前瞻性数据是有限的。由于血栓形成是许多卒中发生的关键机制,因此研究人员在ARIC试验中研究了是否D-二聚体是缺血性卒中发生的危险标志物。研究人员在1992年至1995年测量11415例ARIC患者的D-二聚体,他们没有卒中和冠状动脉心脏疾病。随后研究人员跟踪调查了他们卒中,卒中亚型,和冠状动脉心脏疾病事件直至2

EUR J NEUROL:缺血性卒中患者容易出现视力问题

长期随访发现有1/4的脑梗死患者报告脑梗死后出现视力问题。脑梗死后出现视力问题降低患者的生活质量,增加患者因脑梗死致残率。对于脑梗死后出现视力问题的患者,全面的诊断评估和有针对性的康复治疗是非常重要的。

PLoS One:中国急性缺血性卒中患者静脉溶栓延迟的相关因素

住院延迟减少急性缺血性卒中(AIS)患者静脉溶栓(IVT)的效益,而在中国住院延迟的因素尚不清楚。研究者旨在通过医院队列研究,确定住院延迟相关的特定因素。住院延迟的定义为(入院到用药)DTN时间≥60min(标准延迟标准)或超过所有DTN的75%百分位数(严重延迟的标准)。获得受试者人口学资料,时间间隔(症状开始到入院时间OTD),DTN,及入院到检查时间(DTE),入院到影像学检查时间(DTI)

JAMA Neurol:静脉溶栓前接受抗血小板治疗的患者,颅内出血发生率较高,但预后较好

重要性:静脉组织纤溶酶原激活物(tPA)治疗可改善缺血性卒中的预后;然而,许多患者在急性缺血性卒中前接受了抗血小板治疗,当进行tPA治疗时可能会增加出血的风险。目的:评估进行静脉tPA治疗的缺血性卒中患者在卒中前接受抗血小板治疗患者的风险和收益。设计:这项观察性研究应用美国心脏病协会,美国卒中协会获得指南卒中登记的数据,2009年1月到2015年3月31期间,在1545注册医院中接受tPA治疗的缺